Fosaprepitant
Based on 4 publication(s) in Google Scholar
Fosaprepitant (L-785298) is a proagent of Aprepitant (HY-10052). Fosaprepitant is a neurokinin-1 receptor antagonist, which is development for the prevention of chemotherapy-induced nausea and vomiting (CINV).
It is advisable to consider the salt form (Fosaprepitant dimeglumine) that retains the same biological activity.
For research use only. We do not sell to patients.
- CAS No.: 172673-20-0
- Formula: C23H22F7N4O6P
- Molecular Weight:614.41
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
-
HY-14407A
Fosaprepitant dimeglumineNeurokinin-1 Receptor Antagonist -
HY-10052
AprepitantNeurokinin 1 Receptor Antagonist -
HY-16346
NetupitantNK1 Receptor Inhibitor -
HY-10052R
Aprepitant (Standard)Neurokinin 1 Receptor Antagonist -
HY-14751
RolapitantNK1 Receptor Antagonist -
HY-14407AR
Fosaprepitant dimeglumine (Standard)Neurokinin-1 Receptor Antagonist -
HY-10053
MaropitantNK1 Receptor Antagonist -
HY-P0187
SenktideNK3 Receptor Agonist -
HY-101249
L-732138NK-1 Receptor Antagonist -
HY-15722
SB-222200NK-3 Receptor Antagonist -
HY-19632
FezolinetantNK3R Antagonist -
HY-18006
NKP608NK-1 Receptor Antagonist
Publications Citing Use of MedChemExpress (MCE) Fosaprepitant
More
Biological Activity
Description
IC50 & Target
Neurokinin-1 receptor[1]
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley rats[1]
-
Dosage:30 mg/kg
-
Administration:Intraperitoneal injection, daily, for 7 days
-
Result:Increased the antinociceptive effect of morphine compared to control group.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 172673-20-0
-
Molecular Weight 614.41
-
Formula C23H22F7N4O6P
-
SMILES
O=C1N=C(CN2[C@@H](C3=CC=C(F)C=C3)[C@@H](O[C@H](C)C4=CC(C(F)(F)F)=CC(C(F)(F)F)=C4)OCC2)NN1P(O)(O)=O
-
Synonyms
L-758298
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Acta Pharmacol Sin
Antiemetic drug fosaprepitant exerts anti-tumor effects against NSCLC by targeting FAK to inhibit AKT and JNK/c-Jun pathways. [Abstract]2025 Sep 10. PMID: 40931041 -
Int J Biol Macromol
Inhibition of the oncogenic GTPase dynamin-related protein 1 (DRP1) by the FDA-approved drug fosaprepitant: In silico, biophysical, and in vitro characterization of its anti-myeloma activity. [Abstract]2026 Jun:369:152633. PMID: 42167430 -
Cancer Biol Ther
LncRNA RMRP silence curbs neonatal neuroblastoma progression by regulating microRNA-206/tachykinin-1 receptor axis via inactivating extracellular signal-regulated kinases. [Abstract]2019;20(5):653-665. PMID: 30582709 -
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Fosaprepitant Related Classifications
HY-14407 Related Classifications
Powered by Bioz